Pages that link to "Q56626150"
Jump to navigation
Jump to search
The following pages link to Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer (Q56626150):
Displaying 50 items.
- Uptake of ANG1005, a novel paclitaxel derivative, through the blood-brain barrier into brain and experimental brain metastases of breast cancer (Q24621947) (← links)
- Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer (Q24657308) (← links)
- Current understanding of interactions between nanoparticles and the immune system (Q26345204) (← links)
- Targeted chemotherapy with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in metastatic breast cancer: which benefit for which patients? (Q26745420) (← links)
- Taxanes in the Treatment of Advanced Gastric Cancer (Q26747708) (← links)
- Neoadjuvant nab-paclitaxel in the treatment of breast cancer (Q26748822) (← links)
- Dose-Dense Chemotherapy in Metastatic Breast Cancer: Shortening the Time Interval for a Better Therapeutic Index (Q26751245) (← links)
- A Review of Systemic Treatment in Metastatic Triple-Negative Breast Cancer (Q26752846) (← links)
- Is there a role of nab-paclitaxel in the treatment of advanced non-small cell lung cancer? The data suggest yes (Q26766180) (← links)
- Evolving Evidence of the Efficacy and Safety of nab-Paclitaxel in the Treatment of Cancers with Squamous Histologies (Q26766254) (← links)
- Cytotoxic chemotherapy: Still the mainstay of clinical practice for all subtypes metastatic breast cancer (Q26768140) (← links)
- Taxanes in the elderly patient with metastatic breast cancer (Q26785458) (← links)
- Perspectives in the treatment of pancreatic adenocarcinoma (Q26797248) (← links)
- The role of taxanes in triple-negative breast cancer: literature review (Q26798356) (← links)
- Albumin-bound paclitaxel in solid tumors: clinical development and future directions (Q26798674) (← links)
- Nanotechnology: Future of Oncotherapy (Q26801067) (← links)
- Current approaches in treatment of triple-negative breast cancer (Q26801549) (← links)
- Orchestrating the Tumor Microenvironment to Improve Survival for Patients With Pancreatic Cancer: Normalization, Not Destruction (Q26801834) (← links)
- Cancer nanotheranostics: improving imaging and therapy by targeted delivery across biological barriers (Q26830028) (← links)
- Chemotherapy-enhanced inflammation may lead to the failure of therapy and metastasis (Q26858839) (← links)
- Nanocarriers for diagnosis and targeting of breast cancer (Q26862309) (← links)
- Optimal management of metastatic melanoma: current strategies and future directions (Q26997338) (← links)
- Neuropathic cancer pain: What we are dealing with? How to manage it? (Q26998945) (← links)
- An overview of clinical and commercial impact of drug delivery systems (Q27007143) (← links)
- Delivery of gene silencing agents for breast cancer therapy (Q27008706) (← links)
- Targeted nanotechnology for cancer imaging (Q27010317) (← links)
- Nanotechnology in cancer therapy (Q27023013) (← links)
- Targeted therapy using nanotechnology: focus on cancer (Q27023361) (← links)
- Mesoscale nanoparticles selectively target the renal proximal tubule epithelium (Q27335127) (← links)
- Castor Oil: Properties, Uses, and Optimization of Processing Parameters in Commercial Production (Q28066154) (← links)
- Current Advances of Tubulin Inhibitors in Nanoparticle Drug Delivery and Vascular Disruption/Angiogenesis (Q28077780) (← links)
- Systemic treatment approaches in her2-negative advanced breast cancer-guidance on the guidelines (Q28080469) (← links)
- Pre-clinical immunotoxicity studies of nanotechnology-formulated drugs: Challenges, considerations and strategy (Q28081577) (← links)
- Towards a targeted multi-drug delivery approach to improve therapeutic efficacy in breast cancer (Q28291499) (← links)
- Nanotechnologies for noninvasive measurement of drug release (Q28387499) (← links)
- Simple bioconjugate chemistry serves great clinical advances: albumin as a versatile platform for diagnosis and precision therapy (Q28397980) (← links)
- Assembly of Linear Nano-Chains from Iron Oxide Nanospheres with Asymmetric Surface Chemistry (Q28476700) (← links)
- Human serum albumin and p53-activating peptide fusion protein is able to promote apoptosis and deliver fatty acid-modified molecules (Q28535347) (← links)
- The effectiveness of nano chemotherapeutic particles combined with mifepristone depends on the PR isoform ratio in preclinical models of breast cancer (Q28540889) (← links)
- Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane®) on three treatment schedules in patients with solid tumors (Q29035867) (← links)
- Nanoparticle therapeutics: an emerging treatment modality for cancer (Q29615628) (← links)
- Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine (Q29616728) (← links)
- Clinical Translation of Nanomedicine. (Q30355939) (← links)
- Neurological adverse effects caused by cytotoxic and targeted therapies. (Q30448951) (← links)
- Advances in the field of nanooncology (Q30477604) (← links)
- A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group Study, N057E(1) (Q33394828) (← links)
- A multicenter phase II trial of docetaxel plus gemcitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer (Q33399824) (← links)
- A phase II trial of neoadjuvant nab-paclitaxel, carboplatin, and gemcitabine (ACaG) in patients with locally advanced carcinoma of the bladder (Q33407959) (← links)
- Weekly nab-Rapamycin in patients with advanced nonhematologic malignancies: final results of a phase I trial (Q33410691) (← links)
- Phase II trial of combination nab-paclitaxel, carboplatin and gemcitabine in first line therapy of advanced urothelial carcinoma (Q33411962) (← links)